Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044258 | 0.84 | CHRNA7 (0.57) | CHRNA7CHRNB2CHRNA4CYP1A2CYP3A4 | |
| SCHEMBL12154822 | 0.73 | CFTR (0.52) | LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL31375369 | 0.71 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL703479 | 0.71 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL701677 | 0.70 | CHRNA7 (0.49) | CHRNA7CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL11459028 | 0.70 | CHRNB2 (0.43) | CHRNA7CHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL699563 | 0.69 | CHRNA7 (0.74) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL699428 | 0.69 | CHRNA7 (0.50) | CHRNA7CHRNB2CHRNA4CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11612137 | 0.68 | CHRNB2 (0.42) | CHRNA7CHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL177832 | 0.68 | CFTR (0.46) | LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1053236-A1 | PYRDIYL-BRIIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000034276-A1 | PYRIDYL-BRIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | CHRNA7 11/4885CHRNB2 9/4885CHRNA4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.